All Stories

  1. B cells and atherosclerosis in systemic lupus erythematosus
  2. TNFAIP3 F127C Coding Variation in Greek Primary Sjogren’s Syndrome Patients
  3. Efficacy of a Mediterranean diet supplemented with fatty fish in ameliorating inflammation in paediatric asthma: a randomised controlled trial
  4. Risks in Surrogacy Considering the Embryo: From the Preimplantation to the Gestational and Neonatal Period
  5. Association between male Infertility and seminal plasma levels of growth hormone and insulin-like growth factor-1
  6. Concluding the trilogy: The interaction of 2,2′-dihydroxy-benzophenones and their carbonyl N-analogues with human glutathione transferase M1-1 face to face with the P1-1 and A1-1 isoenzymes involved in MDR
  7. A BAFF Receptor His159Tyr Mutation in Sjögren's Syndrome-Related Lymphoproliferation
  8. FRI0440 Increased Messenger RNA Levels of the Mesenchymal Cadherin-11 in the Peripheral Blood Correlate with Diffuse Skin Involvement in Systemic Sclerosis
  9. A clinicopathological analysis of KISS1 and KISS1R expression in colorectal cancer
  10. Advanced glycation end-products and insulin signaling in granulosa cells
  11. Vitamin D and breast cancer
  12. Vitamin D and prostate cancer
  13. The effect of melatonin on MCF-7 breast cancer cells in vitro
  14. The effect of melatonin on pC3 prostate cancer cells in vitro
  15. Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren’s syndrome: prevalence, clinical and laboratory associations
  16. Statins as Pleiotropic Modifiers of Vascular Oxidative Stress and Inflammation
  17. 44 IGF-1 alternative splicing gene expression as a potential factor in the pathogenesis of Peyronie's disease
  18. The role of the insulin-like growth factor-1 system in breast cancer
  19. Cadherin-11 mRNA transcripts are frequently found in rheumatoid arthritis peripheral blood and correlate with established polyarthritis
  20. Research update for articles published in EJCI in 2012
  21. The Multiple Actions of the Insulin-Like Growth Factor-I Signaling in the Myocardium
  22. Correlation of platelet activating factor and age-related macular degeneration
  23. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome
  24. Peripheral targets in obesity treatment: a comprehensive update
  25. Novel Tools for Prostate Cancer Prognosis, Diagnosis, and Follow-Up
  26. Structural and Functional Properties of Deep Abdominal Subcutaneous Adipose Tissue Explain Its Association With Insulin Resistance and Cardiovascular Risk in Men
  27. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer
  28. Osteoprotegerin expression during the micro- and macrometastatic phases of the osteoblastic metastasis in prostate cancer: therapeutic implications
  29. KISS1 expression in colorectal cancer
  30. Multiplex PCR-Based Detection of Circulating Tumor Cells in Lung Cancer Patients Using CK19, PTHrP, and LUNX Specific Primers
  31. Anabolic effects of interval exercise training on skeletal muscle of patients with chronic heart failure
  32. Dietary glycotoxins affect scavenger receptor expression and the hormonal profile of female rats
  33. THU0012 BAFF Genetic Variants in Lymphomagenesis Associated with Sjogren’s Syndrome
  34. THU0095 Cadherin-11 Gene is Aberrantly Expressed in the Peripheral Blood of Patients with Rheumatoid Arthritis and Strongly Correlates with Multiple Joint Inflammation
  35. Effects of gender and age on hypothalamic-pituitary-adrenal reactivity after pharmacological challenge with low-dose 1-μg ACTH test: a prospective study in healthy adults
  36. Advanced glycation end-products inhibit insulin signaling in human granulosa cells
  37. Preoperative serum lactate dehydrogenase levels in colorectal and gastric cancer: a hospital-based case–control study
  38. Evidence for the Possible Biological Significance of the igf-1 Gene Alternative Splicing in Prostate Cancer
  39. Wnt signaling in cardiovascular physiology
  40. Ocular actions of platelet-activating factor: clinical implications
  41. Serial changes in adiponectin and resistin in critically ill patients with sepsis: Associations with sepsis phase, severity, and circulating cytokine levels
  42. Changes in kinematic variables at various muscle lengths of human elbow flexors following eccentric exercise
  43. The role of adiponectin in human vascular physiology
  44. Biomarkers predicting metabolic syndrome: The role of adiponectin and systemic inflammation
  45. Colorectal Cancer Stem Cells
  46. Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer
  47. Adult-Onset Still’s Disease: From Pathophysiology to Targeted Therapies
  48. Cytokines in Muscle Damage
  49. Response to Asymmetrical Dimethylarginine, Oxidative Stress, and Atherosclerosis
  50. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis
  51. Positive urinary cytology in patients with lung cancer in the absence of obvious urine tract metastases
  52. Methods of detection of circulating melanoma cells: A comparative overview
  53. Role of Asymmetrical Dimethylarginine in Inflammation-Induced Endothelial Dysfunction in Human Atherosclerosis
  54. Endocrine Disruptors and Polycystic Ovary Syndrome (PCOS): Elevated Serum Levels of Bisphenol A in Women with PCOS
  55. Endocrine Disruptors and Polycystic Ovary Syndrome (PCOS): Elevated Serum Levels of Bisphenol A in Women with PCOS
  56. Endocrine Disruptors and Polycystic Ovary Syndrome (PCOS): Elevated Serum Levels of Bisphenol A in Women with PCOS
  57. POSTER VIEWING SESSION - EMBRYOLOGY
  58. Calcium and vitamin D supplementation through fortified dairy products counterbalances seasonal variations of bone metabolism indices: the Postmenopausal Health Study
  59. Detection of the circulating tumor cells in cancer patients
  60. The Impact of Endocrine Disruptors on Endocrine Targets
  61. Preferential expression of IGF-1Ec (MGF) transcript in cancerous tissues of human prostate: Evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells
  62. Discovery of the mitotic selective chromatid segregation phenomenon and its implications for vertebrate development
  63. Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer
  64. Noninvasive Imaging and Radiovirotherapy of Prostate Cancer Using an Oncolytic Measles Virus Expressing the Sodium Iodide Symporter
  65. 9035 Positive urine cytology in patients with lung cancer without obvious urine tract metastases
  66. Serum Testosterone: a Potentially Adjunct Screening Test for the Assessment of the Risk for Prostate Cancer among Men with Modestly Elevated PSA Values (≥3.0 and <10.0 ng/ml)
  67. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology
  68. Detection of circulating tumor cells in bladder cancer patients
  69. Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance
  70. Systemic cytokine response following exercise-induced muscle damage in humans
  71. Engineered measles virus as a novel oncolytic therapy against prostate cancer
  72. The kisspeptin (KiSS-1)/GPR54 system in cancer biology
  73. Autophagy: a target for therapeutic interventions in myocardial pathophysiology
  74. cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines
  75. Mechanisms of the Action of Zoledronic Acid on Human MG-63 Osteosarcoma Cells
  76. Molecular diagnosis of the viral component in cardiomyopathies: pathophysiological, clinical and therapeutic implications
  77. Mechanisms of bone metastasis in prostate cancer: clinical implications
  78. Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS)
  79. Evaluation of a clinical attachment in Primary Health Care as a component of undergraduate medical education
  80. Serum levels of the osteoprotegerin, receptor activator of nuclear factor κ-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction
  81. Experimental hyperthyroidism increases expression of parathyroid hormone-related peptide and type-1 parathyroid hormone receptor in rat ventricular myocardium of the Langendorff ischaemia-reperfusion model
  82. The non-genomic crosstalk between PPAR-γ ligands and ERK1/2 in cancer cell lines
  83. Combination of somatostatin analogues and dexamethasone (antisurvival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis
  84. Luteinising hormone-releasing hormone antagonists in prostate cancer therapy
  85. 314 COMBINATION OF SOMATOSTATIN ANALOG, DEXAMETHASONE, AND STANDARD ANDROGEN ABLATION THERAPY IN STAGE D3 PROSTATE CANCER PATIENTS WITH BONE METASTASES
  86. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostat...
  87. Insulin-Like Growth Factor-1 Isoform mRNA Expression in Women with Endometriosis: Eutopic Endometrium Versus Endometriotic Cyst
  88. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach
  89. RANDOMISED CONTROLLED CLINICAL TRIAL OF A COMBINATION OF SOMATOSTATIN ANALOG AND DEXAMETHASONE PLUS ZOLEDRONATE VS. ZOLEDRONATE IN PATIENTS WITH ANDROGEN ABLATION REFRACTORY PROSTATE CANCER
  90. Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics
  91. The glutamatergic system outside the CNS and in cancer biology
  92. Bone Microenvironment-related Growth Factors, Zoledronic Acid and Dexamethasone Differentially Modulate PTHrP Expression in PC-3 Prostate Cancer Cells
  93. PTH-related protein and Type 1 PTH receptor mRNA expression in ventricular myocardial hypertrophy
  94. PTH-related protein and Type 1 PTH receptor mRNA expression in ventricular myocardial hypertrophy
  95. Transforming growth factor 1 expression in uterine leiomyomas and adjacent myometrium
  96. Transforming growth factor β1 expression in uterine leiomyomas and adjacent myometrium
  97. Combination of Somatostatin Analog, Dexamethasone, and Standard Androgen Ablation Therapy in Stage D3 Prostate Cancer Patients with Bone Metastases
  98. The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
  99. Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells
  100. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study
  101. Urokinase-Type Plasminogen Activator and Insulin-Like Growth Factor-Binding Protein 3 mRNA Expression in Endometriotic Lesions and Eutopic Endometrium
  102. Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists
  103. Angiopoietins in angiogenesis and beyond
  104. Mutation analysis of BrCA1, BrCA2, and p53 versus soluble HLA class I and class II in a case of familial endometriosis
  105. The use of zoledronic acid in painful osseous metastases due to prostate cancer
  106. Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists
  107. Angiopoietins in angiogenesis and beyond
  108. Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer
  109. A Combination Therapy of Dexamethasone and Somatostatin Analog Reintroduces Objective Clinical Responses to LHRH Analog in Androgen Ablation-Refractory Prostate Cancer Patients
  110. A Combination Therapy of Dexamethasone and Somatostatin Analog Reintroduces Objective Clinical Responses to LHRH Analog in Androgen Ablation-Refractory Prostate Cancer Patients
  111. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer
  112. Immunohistochemical localization of insulin-like growth factor–binding protein-3 in eutopic and ectopic endometrial tissues
  113. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone‐refractory prostate cancer: Case report
  114. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: Case report
  115. Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis
  116. Loss of heterozygosity and reduced expression of the CUTL1 gene in uterine leiomyomas
  117. Cell-Cell Interactions in Osteoblastic Metastasis Caused by Advanced Prostate Cancer
  118. Purification and partial sequencing of the major mitogen for human uterine smooth muscle-like cells in leiomyoma extracts.
  119. Mediation of glucocorticoid receptor function by the activation of latent transforming growth factor beta 1 in MG-63 human osteosarcoma cells
  120. Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells
  121. Skeletal metastases in advanced prostate cancer: cell biology and therapy
  122. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP
  123. The Role of Plasma Membrane in the Pathogenesis of Osteoblastic Metastasis
  124. Interaction of antiandrogen-androgen receptor complexes with DNA and transcription activation
  125. Combination Therapy with Flutamide and the LHRH Agonist [D-Trp6, des-Gly-NH210]LHRH Ethylamide in Stage C Prostatic Carcinoma
  126. Heparin-sepharose binding growth factors in peritoneal fluid of women with endometriosis
  127. Pathophysiology of uterine leiomyomas
  128. Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: Characterization of the receptors involved
  129. Preferential mitogenic activity for myoblast-like cells can be extracted from uterine leiomyoma tissues
  130. Human uterus-derived growth substances for rat bone cells and fibroblasts
  131. Application of octadecylsilyl-silica in purification studies related to the nontransformed rat ventral prostate androgen receptor
  132. Effects of human prostatic mitogens on rat bone cells and fibroblasts
  133. Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype.
  134. Complete response of lung metastases caused by prostatic cancer after chronic administration of a gonadotropin-releasing hormone analog, buserelin (HOE 766)
  135. Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either buserelin or orchiectomy Disease aggressivity and its association with response and outcome
  136. Selective osteoblast mitogens can be extracted from prostatic tissue
  137. Studies of the Multiple Molecular Forms of Bioactive Parathyroid Hormone and Parathyroid Hormone-Like Substances
  138. LIST OF CONTRIBUTORS AND DISCUSSANTS
  139. Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: Classification of variables associated with disease outcome
  140. Transphenoidal removal of GH secreting adenomas: method of choice for the treatment of acromegaly
  141. Metastatic prostate cancer: hormone dependency and therapeutic efficacy of GnRH analogues
  142. Comparative study on the effects of orchiectomy or chronic administration of HOE 766 (GnRH-A) in patients with advanced prostatic adenocarcinoma
  143. Suppression of testicular steroidogenesis by the GnRH agonistic analogue buserelin (HOE-766) in patients with prostatic cancer: Studies in relation to dose and route of administration
  144. Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma
  145. SUPPRESSION OF TESTICULAR STEROIDOGENESIS BY THE GnRH AGONISTIC ANALOGUE BUSERELIN (HOE-766) IN PATIENTS WITH PROSTATIC CANCER: STUDIES IN RELATION TO DOSE AND ROUTE OF ADMINISTRATION
  146. Pituitary function in 8 patients with familial pituitary dwarfism
  147. Bone Metastasis Microenvironment Participates in the Development of Androgen Ablation Refractoriness and Chemotherapy Resistance of Prostate Cancer Cells Residing in the Skeleton: Clinical Implications